Developing the medicines that neglected communities have gone without for generations is a lifeline, not a luxury that can wait for easier times or be traded away for short-term savings.
Foreword
There is no question that those hardest hit by the erosion of global health solidarity are the communities DNDi exists to serve.
The principles we were built to defend – scientific excellence, open collaboration, sharing knowledge freely, and treating equity as a guiding principle in medical innovation – are facing stronger headwinds than we have known.
Standing with our partners, we are proud to look back on a year of proof that perseverance is still delivering against the neglect.
highlights
Narrowing in on the next-generation medicines patients deserve
A pipeline of promise
Why sharing science is in our DNA
Open by design
How we are joining forces to keep our promise to neglected patients
Stronger together
In conversation with Violet Naanyu
Patients first
2025 in numbers
projects in our R&D portfolio and an additional 14 projects in the treatment access phase
clinical trial sites in 16 countries
participants enrolled in active DNDi clinical studies
R&D and access partner institutions in 47 countries
DNDi WORLDWIDE
DNDi WORLDWIDE
Clinical sites
- Sleeping sickness
- Leishmaniasis
- Chagas disease
- Parasitic worms
- Mycetoma
- HIV
R&D AND
ACCESS PARTNERS
FOUNDING PARTNERS
DNDi OFFICES- COUNTRIES WITH DNDi ACTIVITIES
OUR PROGRESS
RESEARCH & DEVELOPMENT PORTFOLIO
Acting as a ‘conductor of a virtual orchestra’, we collaborate with research partners around the world at all stages of the R&D process.
Our R&D portfolio includes nine disease areas and 47 projects, 20 of which are focused on identifying or developing new chemical entities.
Partners
DNDi’s worldwide footprint is anchored in endemic countries with 61% of partner institutions based in LMICs
Performance
85% of 2025 DNDi expenditure was for our social mission across R&D and access, capacity strengthening, policy, and advocacy and communication
DNDi has delivered 14 new treatments for six neglected diseases since 2003.
We are deeply grateful to our partners and donors for their collaboration and support.
Photo credits: Brent Stirton-DNDi/Getty Images for DNDi; Laurent Egli-DNDi; Ariane Mawaffo-DNDi; Lameck Ododo-DNDi; Stuart March-DNDi; Ana Rezende-DNDi; JDot-DNDi; Sydelle Willow Smith-DNDi; DNDi; Thoko Chikondi-DNDi; Abang Amirrul Hadi-DNDi.
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
